Contrasting effects of hydroxyurea on cell growth and reduction in Epstein-Barr virus genomes in EBV-infected epithelioid cell lines vs. Burkitt's lymphoma cell lines

Journal of Medical Virology

Volumn 70, Issue 2, 2003, Pages 244-252

  Jiang, Ru ^a   Kanamori, Mikiko ^b   Satoh, Yukio ^a   Fukuda, Makoto ^a   Ikuta, Kazufumi ^a   Murakami, Masanao ^a   Sairenji, Takeshi ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Burkitt's lymphoma cell lines; Cell cycle; EBV genomes; EBV latency; EBV positive epithelioid cell lines; Hydroxyurea

Indexed keywords

CELL NUCLEUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; HYDROXYUREA; VIRUS DNA;

ANTIGEN EXPRESSION; ARTICLE; BURKITT LYMPHOMA; CELL CYCLE; CELL GROWTH; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DAUDI CELL; DNA DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; EPITHELIOID CELL; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LYMPHOMA CELL LINE; RAJI CELL; VIRUS GENOME; VIRUS INFECTION;

BURKITT LYMPHOMA; CELL CYCLE; CELL LINE, TRANSFORMED; DNA, VIRAL; EPITHELIOID CELLS; GENOME, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; HYDROXYUREA; IN SITU HYBRIDIZATION, FLUORESCENCE; TUMOR CELLS, CULTURED; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

EID: 0242416919     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10384     Document Type: Article

References (40)

1. Ambinder RF, Shah WA, Rawlins DR, Hayward GS, Hayward SD. 1990. Definition of the sequence requirements for binding of the EBNA-1 protein to its palindromic target sites in Epstein-Barr virus DNA. J Virol 64:2369-2379.
2. Chodosh J, Holder VP, Gan YJ, Belgaumi A, Sample J, Sixbey JW. 1998. Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype. J Infect Dis 177: 1194-1201.
3. Colby BM, Shaw JE, Elion GB, Pagano JS. 1980. Effect of acyclovir [9-(hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol 34:560-568.
4. Donehower RC. 1992. An overview of the clinical experience with hydroxyurea. Semin Oncol 19:11-19.
5. Fukuda M, Ikuta K, Yanagihara K, Tajima M, Kuratsune H, Kurata T, Sairenji T. 2001. Effect of transforming growth factor-beta 1 on the cell growth and Epstein-Barr virus reactivation in EBV-infected epithelial cell lines. Virology 288:109-118.
6. Gao WY, Cara A, Gallo RC, Lori F. 1993. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type1 replication. Proc Natl Acad Sci USA 90:8925-8928.
7. Gao X, Tajima M, Sairenji T. 1999. Nitric oxide down-regulates Epstein-Barr virus reactivation in epithelial cell lines. Virology 258:375-381.
8. Goulalouic H, Subra F, Mouscadet JF, Carteau S, Auclair C. 1994. Exogenous nucleosides promote the completion of moMLV DNA synthesis in GO-arrested Balb c/3T3 fibroblasts. Virology 200: 87-97.
9. Gussander E, Adams A. 1984. Electron microscopic evidence for replication of circular Epstein-Barr virus genomes in latently infected Raji cells. J Virol 52:549-556.
10. Hampar B, Tanaka A, Nonoyama M, Derge JG. 1974. Replication of the resident repressed Epstein-Barr virus genome during the early S phase (S-1 period) of nonproducer Raji cells. Proc Natl Acad Sci USA 71:631-633.
11. Hirai K, Shirakata M. 2001. Replication licensing of the EBV orip minichromosome. [Epstein-Barr virus and human cancer]. Curr Top Microbiol Immunol 258:13-33.
12. Hopwood P, Crawford DH. 2000. The role of EBV in post-transplant malignancies: a rewiew. J Clin Pathol 53:248-254.
13. Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, Yamamoto N, Tanaka S, Sato E, Osato T. 1994. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA 91:9131-9135.
14. Kanamori M, Tajima M, Satoh Y, Hoshikawa Y, Miyazawa Y, Okinaga K, Kurata T, Sairenji T. 2000. Differential effect of TPA on cell growth and Epstein-Barr virus reactivation in epithelial cell lines derived from gastric tissues and B cell line Raji. Virus Genes 20: 117-125.
15. Kanamori M, Murakami M, Takahashi T, Kamada N, Tajima M, Okinaga K, Miyazawa Y, Kurata T, Sairenji T. 2001. Spontaneous reduction in Epstein-Barr virus (EBV) DNA copy number in EBV-infected epithelial cell lines. Microbes Infect 3:1085-1091.
16. Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H, Clifford P. 1968. Surface IgM kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res 28:1300-1310.
17. Komano J, Sugiura M, Takada K. 1998. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J Virol 72:9150-9156.
18. Lin J, Johannsen E, Robertson E, Kieff E. 2002. Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2. J Virol 76:232-242.
19. Montaner JSG, Zala C, Conway B, Raboud J, Patenaude P, Rae S, O'Shaughnessy MV, Schechter MT. 1997. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trails network protocol 080. J Infect Dis 175:801-806.
20. Moore EC, Hurlbert RB. 1989. The inhibition of ribonucleotide diphosphate reductase by hydroxyurea, guanazole and pyrazoloimadazole (IMPY). In: Cory JA, Cory AH, editors. Inhibitors of ribonucleotide diphosphate reductase activity. New York: Pergamon. p 115-202.
21. Murakami M, Hoshikawa Y, Satoh Y, Ito H, Tajima M, Okinaga K, Miyazawa Y, Kurata T, Sairenji T. 2000. Tumorigenesis of Epstein-Barr virus-positive epithelial cell lines derived from gastric tissues in the SCID mouse. Virology 277:20-26.
22. Nambo A, Inoue K, Adachi-Takasawa K, Takada K. 2002. Epstein-Barr virus RNA confers resistance to interferon-α-induced apoptosis in Burkitt's lymphoma. EMBO J 21:954-965.
23. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. 1995. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 333:693-698.
24. Pulvertaft RJV. 1965. A study of malignant tumors in Nigeria by short-term tissue culture. J Clin Pathol 18:261-273.
25. Raab-Traub N, Flynn K. 1986. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47:883-889.
26. Reedman BM, Hilgers J, Hilgers F, Klein G. 1975. Immunofluorescence and anti-complement immunofluorescence absorption tests for quantitation of Epstein-Barr virus-associated antigens. Int J Cancer 15:566-571.
27. Sairenji T, Tajima M, Kanamori M, Takasaka N, Gao X, Murakami M, Okinaga K, Satoh Y, Hoshikawa Y, Ito H, Miyazawa Y, Kurata T. 2001. Characterization of EBV-infected epithelial cell lines from gastric cancer-bearing tissues. [Epstein-Barr virus and human cancer]. Curr Top Microbiol Immunol 258:185-198.
28. Satoh T, Hoshikawa Y, Satoh Y, Kurata T, Sairenji T. 1998. The interaction of mitogen-activated protein kinase to Epstein-Barr virus activation in Akata cells. Virus Genes 18:57-64.
29. Satoh T, Fukada M, Sairenji T. 2002. Distinct patterns of mitogen-activated protein kinase phosphorylation and Epstein-Barr virus gene expression in Burkitt's lymphoma cell lines versus B lymphoblastoid cell lines. Virus Genes 25:15-21.
30. Shimizu N, Tanabe Tochikura A, Kuroiwa Y, Takada K. 1994. Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol 68:6069-6073.
31. Sixbey JW, Pagano JS. 1985. Epstein-Barr virus transformation of human B lymphocyte despite inhibition of viral polymerase. J Virol 53:299-301.
32. Slobod KS, Taylor GH, Sandlund JT, Furth P, Helton KJ, Sixbey JW. 2000. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet 356:1493-1494.
33. Tajima M, Komuro M, Okinaga K. 1998. Establishment of Epstein-Barr virus-positive human gastric epithelial cell lines. Jpn J Cancer Res 89:262-268.
34. Takada K, Ono Y. 1989. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol 63:445-449.
35. Takasaka N, Tajima M, Okinaga K, Satoh Y, Hoshikawa Y, Katsumoto T, Kurata T, Sairenji T. 1998. Productive infection of Epstein-Barr virus (EBV) in EBV-genome-positive epithelial cell lines (GT38 and GT39) derived from gastric tissues. Virology 274:152-159.
36. Tokunaga M, Land CE, Uemura Y, Tokudome T, Tanaka S, Sato E. 1993. Epstein-Barr virus gastric carcinoma. Am J Pathol 143:1250-1254.
37. Trivedi P, Spinsanti P, Cuomo L, Volpe M, Takada K, Frati L, Faggioni A. 2001. Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain. J Virol 75:4929-4935.
38. Von Hoff DD, Waddelow T, Forseth B, Davidson K, Scott J, Wahl G. 1991. Hydroxyurea accelerates loss of extrachromosomally amplified genes from tumor cells. Cancer Res 51:6273-6279.
39. Von Hoff DD, McGill JR, Forseth BJ, Davidson KK, Bradley TP, Van Devanter DR, Wahl GM. 1992. Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity. Proc Natl Acad Sci USA 89:8165-8169.
40. Yarbro JW. 1992. Mechanisms of action of hydroxyurea. Semin Oncol 19:1-10.